Hantech Bio-Technology Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	774.78	625.14	302.52
Revenue Growth (YoY)	-	106.65%	-
Cost of Revenue	438.4	344.29	175.89
Gross Profit	336.38	280.85	126.63
Selling, General & Admin	99.49	88.34	61.11
Research & Development	8.4	7.37	8.09
Operating Expenses	107.81	95.15	69.8
Operating Income	228.57	185.71	56.84
Interest Expense	-4.64	-2.12	-1.47
Interest & Investment Income	0.86	0.65	0.27
Currency Exchange Gain (Loss)	0.39	-0.03	2.57
Other Non Operating Income (Expenses)	0.93	0.46	0.07
EBT Excluding Unusual Items	226.11	184.68	58.28
Gain (Loss) on Sale of Assets	-0.46	-0.11	-0.55
Pretax Income	225.65	184.57	57.73
Income Tax Expense	47.02	37.04	11.87
Earnings From Continuing Operations	178.63	147.53	45.86
Minority Interest in Earnings	0.33	0.59	1.61
Net Income	178.96	148.12	47.47
Net Income to Common	178.96	148.12	47.47
Net Income Growth	-	212.00%	-
Shares Outstanding (Basic)	25	25	23
Shares Outstanding (Diluted)	26	26	24
Shares Change (YoY)	-	8.22%	-
EPS (Basic)	7.10	5.90	2.05
EPS (Diluted)	6.90	5.77	2.00
EPS Growth	-	188.46%	-
Free Cash Flow	-127.61	-102.03	-19.7
Free Cash Flow Per Share	-4.92	-3.98	-0.83
Dividend Per Share	0.769	0.769	0.669
Dividend Growth	-	14.99%	-
Gross Margin	43.42%	44.93%	41.86%
Operating Margin	29.50%	29.71%	18.79%
Profit Margin	23.10%	23.69%	15.69%
Free Cash Flow Margin	-16.47%	-16.32%	-6.51%
EBITDA	247.45	198.27	68.54
EBITDA Margin	31.94%	31.72%	22.66%
D&A For EBITDA	18.87	12.56	11.71
EBIT	228.57	185.71	56.84
EBIT Margin	29.50%	29.71%	18.79%
Effective Tax Rate	20.84%	20.07%	20.56%

Source: S&P Capital IQ. Standard template. Financial Sources.